To date, two SMO inhibitors (i.e. vismodegib, sonidegib) have been approved by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for treating locally advanced basal cell carcinoma. This evidence concerns the gene SMO and basal cell carcinoma.